VERTEX PHARMACEUTICALS INCORPORATED Vertex Pharmaceuticals Incorporated Share Price
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 397.5 USD | -0.06% |
|
+0.81% | -2.31% |
| Sales 2024 * | 10.72B 894B | Sales 2025 * | 11.74B 979B | Capitalization | 103B 8,566B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.86B 322B | Net income 2025 * | 4.44B 371B | EV / Sales 2024 * | 8 x |
| Net cash position 2024 * | 16.91B 1,410B | Net cash position 2025 * | 21.28B 1,775B | EV / Sales 2025 * | 6.94 x |
| P/E ratio 2024 * |
26.7
x | P/E ratio 2025 * |
23.2
x | Employees | 5,400 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vertex Pharmaceuticals Incorporated
More recommendations
More press releases
More news
| 1 day | -0.06% | ||
| 1 week | +0.81% | ||
| Current month | -4.91% | ||
| 1 month | -5.01% | ||
| 3 months | -7.60% | ||
| 6 months | +10.02% | ||
| Current year | -2.31% |
1 week
393.00
406.86
1 month
391.01421.45
Current year
391.01448.40
1 year
320.01448.40
3 years
176.36448.40
5 years
164.07448.40
10 years
62.41448.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 01/17/01 | |
Jeffrey Leiden
CHM | Chairman | 68 | 08/09/08 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 10/19/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 08/17/08 |
Jeffrey Leiden
CHM | Chairman | 68 | 08/09/08 |
Bruce Sachs
BRD | Director/Board Member | 64 | 01/98/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.67% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 397.5 | -0.06% | 682,467 |
| 25/24/25 | 397.7 | -0.76% | 787,700 |
| 24/24/24 | 400.8 | -1.02% | 806,473 |
| 23/24/23 | 404.9 | +1.25% | 1,070,343 |
| 22/24/22 | 399.9 | +1.43% | 1,393,886 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
07/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
397.5
USD
Average target price
459.7
USD
Spread / Average Target
+15.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B | |
| -24.71% | 8.24B |
- Stock Market
- Equities
- VRTX Stock
